Back to search

Peptide record

TPDB91802

HPRP-A1 Antibacterial Anticancer Antifungal Toxicity standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91802
HPRP-A1
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP Peptipedia CancerPPD 2.0 CAFPdb
standard
No
A 15-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
C-terminal: Amidation N-terminal: Acetylation
Sequence
Ac-FKKLKKLFSKLWNWK-NH2
Physicochemical Analysis
C101H156N24O18
ARDCEQGHIMPTYV
K
1994.50
11.21
6
0
7
+6
-1.15
-0.833
78.00
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
11000
551.52
2
Residue Composition
number
0
A
0
R
1
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
3
L
6
K
0
M
2
F
0
P
1
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 3 K: 6 M: 0 F: 2 P: 0 S: 1 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
15
C101H156N24O18
1994.50
11.21
+6
-1.15
-0.833
Amidation
L
Linear
Acetylation
Anticancer
Helicobacter pylori N-terminal region of Helicobacter pylori ribosomal protein L1
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50 = 6.1 ± 0.02 µM
Anticancer
6.1

Target

Skin Cancer
B-16
Skin

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 5.2 ± 0.14 µM
Anticancer
5.2

Target

Gastric cancer
SGC-7901
Stomach

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015
Evidence 3 Activity

Activity

IC50
IC50 = 7.7 ± 0.23 µM
Anticancer
7.7

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015
Evidence 4 Activity

Activity

IC50
IC50 = 3.5 ± 0.03 µM
Anticancer
3.5

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2015
Evidence 5 Activity

Activity

IC50 between 0.5 and 1 µg/mL
Anticancer

Target

Colorectal Cancer
CT-26
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021
Evidence 6 Activity

Activity

IC50
IC50 ~ 0.5 µg/mL
Anticancer
0.5 µg/mL

Target

Colon Cancer
HT-29
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2021